Research groups
Colleges
DPhil projects available
AKR1C1 as a therapeutic target in non-alcholoic fatty liver diease and hepatocellular carcinoma
Jeremy Tomlinson
MB BCh, PhD, FRCP
Professor of Metabolic Endocrinology
My work tries to better understand and treat metabolic diseases, in particular, non-alcholic fatty liver disease (NAFLD). Our work has focused on the role of steroid hormones and their metabolism in the development, assessment and treatment of metabolic diseases including NAFLD, obesity and type 2 diabetes. Our previous work has shown that altering steroid hormone metabolism can have a potent impact on the function of both liver and adipose tissue to store fat. Our future work will use steroid biomarkers not only to stage disease severity, but to predict progression. In addition, by altering tissue specific-metabolism, we hope to limit the side effects of prescribed steroids.
Key publications
-
Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man.
Journal article
Hazlehurst JM. et al, (2016), J Clin Endocrinol Metab, 101, 103 - 113
-
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
Journal article
Armstrong MJ. et al, (2016), J Hepatol, 64, 399 - 408
-
5α-Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes.
Journal article
Nasiri M. et al, (2015), Endocrinology, 156, 2863 - 2871
Recent publications
-
AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease.
Journal article
Nikolaou N. et al, (2019), Metabolism
-
Increased central adiposity and decreased subcutaneous adipose tissue 11β-hydroxysteroid dehydrogenase type 1 are associated with deterioration in glucose tolerance-A longitudinal cohort study.
Journal article
Crowley RK. et al, (2019), Clin Endocrinol (Oxf), 91, 72 - 81
-
Recovery of the hypothalamo-pituitary-adrenal axis following trans-sphenoidal adenomectomy for non-ACTH secreting macroadenomas.
Journal article
Pofi R. et al, (2019), J Clin Endocrinol Metab
-
Author's Reply: Does increased 11 β HSD-1 activity induce adverse metabolic phenotype only in lean?
Journal article
Crowley RK. et al, (2019), Clin Endocrinol (Oxf), 90, 849 - 850
-
Human and murine steroid 5β-reductases (AKR1D1 and AKR1D4): insights into the role of the catalytic glutamic acid.
Journal article
Chen M. et al, (2019), Chem Biol Interact, 305, 163 - 170